Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
ProMIS Neurosciences ( (PMN) ) has shared an announcement.
On June 12, 2025, ProMIS Neurosciences held its Annual Meeting where shareholders voted on three key proposals. The election of seven directors was confirmed, the appointment of Baker Tilly US, LLP as the independent accounting firm was ratified, and the 2025 Stock Option and Incentive Plan was approved. These decisions are expected to shape the company’s governance and financial strategies moving forward.
The most recent analyst rating on (PMN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on ProMIS Neurosciences stock, see the PMN Stock Forecast page.
Spark’s Take on PMN Stock
According to Spark, TipRanks’ AI Analyst, PMN is a Underperform.
ProMIS Neurosciences faces significant financial hurdles, with no current revenue and ongoing operational losses, leading to a weak overall financial performance. The technical analysis indicates the stock is under pressure, and the valuation reflects challenges with a negative P/E ratio. While recent corporate events show promise in terms of future growth potential, they do not offset the immediate financial challenges. The overall score reflects the need for cautious optimism, as the company must improve its financials and achieve sustainable revenue generation.
To see Spark’s full report on PMN stock, click here.
More about ProMIS Neurosciences
Average Trading Volume: 43,205
Technical Sentiment Signal: Strong Sell
Current Market Cap: $17.49M
Find detailed analytics on PMN stock on TipRanks’ Stock Analysis page.